前收市價 | 66.14 |
開市 | 66.03 |
買盤 | 65.69 x 100 |
賣出價 | 66.30 x 100 |
今日波幅 | 65.68 - 66.19 |
52 週波幅 | 36.99 - 70.81 |
成交量 | |
平均成交量 | 145,361 |
市值 | 1.386B |
Beta 值 (5 年,每月) | 0.80 |
市盈率 (最近 12 個月) | 77.72 |
每股盈利 (最近 12 個月) | 0.85 |
業績公佈日 | 2024年5月10日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 79.80 |
Data from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a statistically significant difference in treating patients with Parkinson's disease compared with a placebo.
The approval of GSK's 5-in-1 meningococcal ABCWY vaccine candidate, MenABCWY, could provide the broadest meningococcal serogroup coverage and lead to simplified immunization.
Aptevo (APVO) plunges after it issues secondary shares, which are not only issued at a significant discount but also substantially dilute the existing shareholder base.